An accelerated growth rate of acquired melanocytic nevi (AMN) following growth hormone therapy in children raises a concern about the potential risk for melanoma.1 Survivors of childhood malignancies may have increased numbers of AMN.2 Because the number of AMN, rather than their growth rate, is a known risk factor for melanoma,3 we assessed the AMN counts in a cross-sectional study of survivors of childhood neoplasia with secondary growth hormone deficiency (GHD).
Subjects and Methods.
The patient group (group 1) consisted of 20 children (13 males and 7 females) with secondary GHD due to chemotherapy or radiotherapy treated with recombinant human growth hormone (Protropin, Genentech Inc, South San Francisco, Calif) 0.3 mg/kg per week. Prior neoplasms included medulloblastoma (n=7), craniopharyngioma (n=5), histiocytosis × (n=3), astrocytoma (n=2), ependymoma (n=1), meningioma (n=1), and rhabdomyosarcoma (n=1). Chemotherapy was administered to 8 children and radiotherapy was administered to 17 children.There were
Zvulunov A, Wyatt DT, Rabinowitz LG, Esterly NB. Effect of Growth Hormone Therapy on Melanocytic Nevi in Survivors of Childhood Neoplasia. Arch Dermatol. 1997;133(6):795–796. doi:10.1001/archderm.1997.03890420141026
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: